Peptides, mAbs, bispecifics, oh my! clinical pharmacology challenges in the development of biologics

Publisher： John Wiley & Sons Inc

E-ISSN： 1552-4604|55|S3|S1-S3

ISSN： 0091-2700

Source： JOURNAL OF CLINICAL PHARMACOLOGY (ELECTRONIC), Vol.55, Iss.S3, 2015-03, pp. : S1-S3

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Considerations for clinical pharmacology studies for biologics in emerging markets

By  

JOURNAL OF CLINICAL PHARMACOLOGY (ELECTRONIC), Vol. 55, Iss. S3, 2015-03 ,pp. : S116-S122

John Wiley & Sons Inc

Access to resources Recommend Favorite

Inhibiting complement regulators in cancer immunotherapy with bispecific mAbs

By Gelderman Kyra A   Lam Suzanne   Gorter Arko  

Expert Opinion on Biological Therapy, Vol. 5, Iss. 12, 2005-12 ,pp. : 1593-1601

Informa Healthcare

Access to resources Recommend Favorite

What's in the Pipeline? Prospects for Monoclonal Antibodies (mAbs) as Therapies for Lung Diseases

By Li L.   Das A.M.   Torphy T.J.   Griswold D.E.  

Pulmonary Pharmacology & Therapeutics, Vol. 15, Iss. 5, 2002-10 ,pp. : 409-416

Academic Press

Access to resources Recommend Favorite

Human HLA-DR mAbs promising against lymphoma

By  

Inpharma, Vol. 1, Iss. 1355, 2002-01 ,pp. : 7-7

Adis International

Access to resources Recommend Favorite

Controlling the Glycosylation Profile in mAbs Using Time-Dependent Media Supplementation

By Radhakrishnan Devesh   Robinson Anne S.   Ogunnaike Babatunde A.  

Antibodies, Vol. 7, Iss. 1, 2017-12 ,pp. : 1-1

MDPI

Access to resources Recommend Favorite